Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Piper Sandler
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by equities research analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued on Monday, Marketbeat reports. They currently have a $36.00 price target on the biotechnology company’s stock, down from their prior price target of $70.00. Piper Sandler’s […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by equities research analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued on Monday, Marketbeat reports. They currently have a $36.00 price target on the biotechnology company’s stock, down from their prior price target of $70.00. Piper Sandler’s […]
